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Crystal Structures of Candida albicans
N-Myristoyltransferase with Two Distinct Inhibitors
membranes and that facilitates interactions with hy-
drophobic protein domains [6, 7]. Nmt participates in
diverse biological processes, including signal transduc-
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Kenji Morikami,1 Yasuhiko Shiratori,1
Hirosato Ebiike,1 Kenichi Kawasaki,1 tion cascades [8] and apoptosis [9].
Nmt from Saccharomyces cerevisiae has been clonedYuko Aoki,1 Nobuo Shimma,1 Allan D’Arcy,2,4
Fritz K. Winkler,2,5 David W. Banner,2 and well characterized in its enzymatic function, sub-
strate and acyl-CoA binding specificity [10]. Substrateand Tatsuo Ohtsuka1
1Nippon Roche Research Center binding and kinetic studies with myristoyl-CoA and its
analogs have indicated that catalysis by Nmt occurs via200 Kajiwara
Kamakura, Kanagawa 247-8530 an ordered Bi-Bi mechanism [11]. The apo-enzyme first
forms a myristoyl-CoA:Nmt binary complex with highJapan
2 Pharmaceutical Research selectivity for myristoyl-CoA. A peptide substrate then
binds to generate a myristoyl-CoA:Nmt:peptide ternaryF. Hoffmann-La Roche Ltd.
CH-4070 Basel complex. Following the catalytic transfer of myristate
from CoA to peptide substrate, free CoA is released firstSwitzerland
and the N-myristoylated peptide second.
Several Nmts have been cloned from the important
pathogenic fungi Candida albicans [12], CryptococcusSummary
neoformans [13], and Aspergillus fumigatus (K. Hashido,
personal communication). Genetic experiments haveMyristoyl-CoA:protein N-myristoyltransferase (Nmt) is
established that the NMT gene is essential for vegetativea monomeric enzyme that catalyzes the transfer of
growth and survival of C. albicans [14] and C. neo-the fatty acid myristate from myristoyl-CoA to the
formans [15]. Human Nmt has also been cloned andN-terminal glycine residue of a variety of eukaryotic
characterized [16]. C. albicans Nmt has 451 amino-acidand viral proteins. Genetic and biochemical studies
residues, with a sequence identity of 45% to the humanhave established that Nmt is an attractive target for
enzyme. Clear differences in the peptide-substrateantifungal drugs. We present here crystal structures
specificity between fungal and human Nmts have beenof C. albicans Nmt complexed with two classes of
exploited, and Nmt has been identified as a potentialinhibitor competitive for peptide substrates. One is a
chemotherapeutic target for antifungal agents [17–19].peptidic inhibitor designed from the peptide substrate;
A peptidomimetic inhibitor, SC-58272, showing selec-the other is a nonpeptidic inhibitor having a benzofuran
tivity between the C. albicans and human enzymes hascore. Both inhibitors are bound into the same binding
been designed and synthesized by elaboration of pep-groove, generated by some structural rearrangements
tide substrates (Table 1) [20]. SC-58272 is competitiveof the enzyme, with the peptidic inhibitor showing a
for the binding of peptide substrates, contingent uponsubstrate-like binding mode and the nonpeptidic in-
prior binding of myristoyl-CoA as for a peptidic inhibitor,hibitor binding differently. Further, site-directed muta-
ALYASKLS-NH2 [17], derived from the N-terminal frag-genesis for C. albicans Nmt has been utilized in order
ment of S. cerevisiae Arf2p. Recently, we identified se-to define explicitly which amino acids are critical for
lective nonpeptidic inhibitors by in vitro enzyme inhibi-inhibitor binding. The results suggest that the enzyme
tory assay screening and then optimized them using ahas some degree of flexibility for substrate binding
medicinal chemistry approach (Table 1) [21, 22]. Com-and provide valuable information for inhibitor design.
plete details of our efforts to develop the nonpeptidic
compounds will be published elsewhere. These inhibi-Introduction
tors are competitive for the binding of peptide sub-
strates as well as SC-58272 and are highly selective forMyristoyl-CoA:protein N-myristoyltransferase (Nmt; EC
C. albicans Nmt over the human Nmt. Some of them2.3.1.97) catalyzes the transfer of the 14-carbon satu-
showed in vivo antifungal activity in an animal model.rated fatty acid myristate (tetradecanoate; C14:0) from
Other types of nonpeptidic inhibitors have been re-myristoyl-CoA to the N-terminal glycine residue of a
ported, although their in vivo efficacy has not been de-variety of eukaryotic cellular and viral proteins [1–3].
scribed [23–25].This covalent modification via an amide linkage occurs
X-ray crystal structures of Nmt from two different spe-cotranslationally in eukaryotes after the first methionine
cies have been determined. The C. albicans apo-enzymeis removed by a methionyl-aminopeptidase [4, 5]. The
structure has been refined to 2.45 A˚ resolution (Proteincovalent attachment of myristate results in an increase
Data Bank ID code 1NMT) [26]. The structure of S. cere-of lipophilicity that triggers association with cellular
visiae Nmt with a nonhydrolyzable myristoyl-CoA analog
[S-(2-oxo)pentadecyl-CoA] and a dipeptide inhibitor
3 Correspondence: satoshi.sogabe@roche.com (SC-58272) has been refined to 2.9 A˚ resolution (Protein4 Present address: Morphochem AG, Schwarzwaldallee 215, WRO-
Data Bank ID code 2NMT) [27]. Recently, the binary1055, CH-4058 Basel, Switzerland.
complex of S. cerevisiae Nmt with myristoyl-CoA and5 Present address: Life Sciences, Paul Scherrer Institut, CH-5232
Villigen PSI, Switzerland. the ternary complex of S. cerevisiae Nmt with S-(2-oxo)
Chemistry & Biology
1120
pentadecyl-CoA and an octapeptide substrate (GLY-
ASKLA) have been determined at 2.2 A˚ and 2.5 A˚ resolu-
tion, respectively (Protein Data Bank ID codes 1IIC and
1IID) [28]. The structure of the C. albicans apo-enzyme
revealed a unique / fold [26]. The ternary complexes
of S. cerevisiae Nmt have addressed substrate speci-
ficity and the catalytic mechanism [27, 29]. The three-
dimensional structure of C. albicans Nmt with nonpep-
tidic inhibitors would also contribute to the rational
design of potent compounds to selectively inhibit the
fungal enzyme while remaining nontoxic to mammalian
cells. We present here the determination of the crystal
structures of the complex of C. albicans Nmt with two
different classes of inhibitor. One is the peptidomimetic
inhibitor (SC-58272 [30]), and the other is nonpeptidic
(Table 1). We also describe an extensive mutagenesis
study to elucidate the inhibitor contact regions. These
results provide not only valuable information for struc-
ture-based drug design but also some insights into the
structural features of the catalytic reaction of Nmt.
Results and Discussion
Overall Structure
The ternary complex of C. albicans Nmt with myristoyl-
CoA and SC-58272, a peptidic inhibitor, was determined
at 2.3 A˚ resolution. The model contains 392 residues
(residues 60 to 451), myristoyl-CoA, SC-58272, and 123
solvent molecules, and has good stereochemistry (Table
2). The average root-mean-square deviation (rmsd) of
C atoms between the two molecules in the asymmetric
unit is 0.6 A˚. Crystal structures of C. albicans Nmt with
nonpeptidic inhibitors were also determined at 3.2 (or
3.5) A˚ resolution by soaking experiments. Crystals of
the apo-enzyme had relatively higher solvent contents
than those of the ternary complex, which may explain
the susceptibility of these crystals to X-ray damage. The
model is comprised of residues 71 to 107 and 114 to 451
of each Nmt monomer. The average rmsd of C atoms
among the four molecules (molecules A to D) in the
asymmetric unit was 0.4 A˚, the structure being refined
with tight noncrystallographic symmetric restraints be-
tween the polypeptide chains for residues 82 to 451.
The inhibitors were bound to two of the four molecules
(A and C) in the asymmetric unit, whereas the other two
molecules (B and D) had relatively higher B factors with
poor electron density. Average B factors for molecules
A and C were 38.4 A˚2 and 38.2 A˚2 , respectively, whereas
those of molecules B and D were 48.7 A˚2 and 56.4 A˚2 ,
respectively. Molecule C is the focus of the structural
discussion in this work. As evidenced by its poor elec-
tron density, the loop of residues 108 to 113 (defined
as the Ab loop [28], see below) was disordered in C.
albicans Nmt complexed with nonpeptidic inhibitors as
well as the C. albicans apo-enzyme crystallized with
different crystallographic symmetry [26].
The protein fold of C. albicans Nmt in complexes with
inhibitors consists of a compact saddle-shaped  sheet
flanked on both of its faces by several  helices. The
overall structure is the same as those of the S. cerevisiae
Nmt complex [27] and the C. albicans apo-enzyme [26],
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with typical rmsds of C atoms of 1.9 A˚ and 1.2 A˚,
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Table 2. Refinement Statistics
Enzyme CaNmt
Cofactor Myristoyl-CoA
Compound SC-58272 CaNmt – 2 CaNmt – 4 CaNmt – 5
Crystal properties
Space group P212121 P212121 P212121 P212121
Unit cell (A˚) 58.7, 95.3, 176.5 93.3, 94.9, 267.9 93.6, 96.7, 270.1 93.3, 96.9, 269.3
Data collection
Resolution (A˚) 2.3 3.5 3.2 3.2
Completeness (%) 92.2 93.7 81.0 99.0
Rsyma (%) 0.065 0.118 0.098 0.072
Refinementb
Resolution range (A˚) 40–2.3 (2.38–2.30) 40–3.5 (3.63–3.50) 40–3.2 (3.31–3.20) 40–3.2 (3.31–3.20)
Completeness (%) 92.3 (71.4) 93.8 (84.2) 81.0 (48.3) 98.9 (99.7)
Rc (working set) 0.192 (0.244) 0.321 (0.363) 0.297 (0.370) 0.284 (0.327)
Rfreed (test set) 0.223 (0.286) 0.373 (0.439) 0.346 (0.414) 0.366 (0.418)
B values
Mean B value (overall, A˚2) 35.0 42.2 45.8 45.4
RMS deviations from ideal values
Bond lengths (A˚) 0.007 0.011 0.010 0.010
Bond angles (degrees) 1.56 1.69 1.58 1.44
a Rsym  j|I  Ij|/I, where Ij is the observed integrated intensity of the jth reflection and I is the average integrated intensity.
b Values in parentheses refer to data in the highest resolution shell.
c R  hkl||Fobs||Fcalc||/hkl|Fobs|, where Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively.
d Rfree is calculated with 5% of the reflection set aside randomly.
respectively. This structural similarity is reasonable presumed to be crucial for the recognition and binding
of myristoyl-CoA [27]. However, in our structure, in whichsince the sequence identity between the two enzymes
is 54%. Some structural differences of peptide confor- the N-terminal 59 residues were missing, the myristoyl-
CoA binding has a similar conformation. Kinetic experi-mation were observed on the molecular surface which
correlate with amino-acid sequence differences. The ments showed that deletion of the amino-terminal 59
residues has no apparent effect on its activity in in vitroN-terminal half forms most of the myristoyl-CoA binding
site, while the C-terminal half contributes largely to the enzymatic assays. The dimer interactions observed in
these crystals seem to be an artifact of crystallizationpeptide-substrate binding site, although the molecule
is regarded as a single-domain structure. The bound and seem not to be related to the enzymatic activity.
conformation of myristoyl-CoA was almost the same as
those of myristoyl-CoA and myristoyl-CoA analog in the
Binding Mode of SC-58272, a Peptidic Inhibitor
complexes of S. cerevisiae Nmt. On the other hand,
A close-up view of the binding site of SC-58272 is pre-
some conformational rearrangements were observed in
sented in Figure 2A. The inhibitor lies in an extended
the vicinity of the substrate binding site (see below).
conformation in a long groove formed by  strands and
In the ternary complex, the protein is observed as a
the loops of residues 238 to 249 of the C-terminal half
dimer in which residues 60 to 81 of one molecule form
and residues 106 to 115 of the N-terminal half. Moreover,
an extended structure along the surface of the other
the bound myristoyl-CoA itself forms a part of the bind-
molecule and vice versa, i.e., the N-terminal “tails” cross
ing site for SC-58272. A total of 84% (833 A˚2 ) of the
over (Figure 1). It is likely that for a monomer in solution,
surface area of SC-58272 is buried in the long groove
the N-terminal tail packs in a very similar way against
of the enzyme. This value is similar to those of the ternary
the rest of the molecule. From the S. cerevisiae structure,
complex of S. cerevisiae Nmt with a myristoyl-CoA ana-
the N-terminal 310-helix (A	: residues 39 to 45 [27]) was log and SC-58272. The bound conformation of the inhibi-
tor is identical to that of SC-58272 in the complex of
the S. cerevisiae Nmt [27]. The 2-methylimidazole group,
which was designed to mimic the N terminus of a peptide
substrate, is buried and interacts with the carboxyl
group of the C-terminal residue (Leu451). The aliphatic
chain between the imidazole ring and the benzene ring
is bent and has contacts with myristoyl-CoA, thus guid-
ing the imidazole ring to the C-terminal carboxylate.
Several hydrophobic residues, Val108, Phe117, Tyr225,
and Phe339, make van der Waals contacts with the
benzene ring. The hydroxyl group of serine, which isFigure 1. Ribbon Model of C. albicans Nmt in Complex with Myris-
completely buried, is hydrogen bonded to the side-chaintoyl-CoA and SC-58272
imidazole group of His227 and to the main-chain amideMyristoyl-CoA and SC-58272 is shown as a stick model. Color codes
group of Gly413. The amino group of lysine is sur-of atoms are as follows: oxygen atoms, red; nitrogen atoms, blue;
carbon atoms, gray. rounded by the side chains of negatively charged resi-
Chemistry & Biology
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Figure 2. The Binding Mode of the Inhibitors
The inhibitors SC-58272 (A) and compound
5 (B) are outlined by the 
A-weighted Fo-Fc
electron density map at the 3
 level with final
model of the protein. Atoms are colored as
in Figure 1, except that carbon atoms of the
protein and the inhibitor are gray and yellow,
respectively. Dashed magenta lines indicate
hydrogen bond interactions. A schematic
drawing of the interactions of compound 5 is
shown in (C).
dues Asp110, Asp112, and Asp412. The aliphatic moiety C. albicans Nmt with compounds 2 and 4 were also
determined (Figure 3).of lysine is covered by the aromatic side chains of
Phe115 and Phe240. The peptide moiety is also bound The nonpeptidic inhibitors are situated in the region of
the substrate binding site, but with different interactionsto the main-chain amide nitrogen and the side-chain
carboxyl group of Asp412. The 2-cyclohexylethyl amide from those of SC-58272 (Figure 2C). The benzofuran
moiety is located at the center of a deep pocket, sur-interacts with Pro229 and Tyr 256 and is positioned in
an open-ended groove that would allow Nmt to accom- rounded by hydrophobic residues. The pocket of the
modate a variety of substrate proteins. inhibitor binding site is composed of aromatic residues
Tyr107, Phe115, Phe117, Tyr119, Phe176, Tyr225,
Phe240, Tyr256, Tyr335, Phe339, and Tyr354. The ben-Binding Mode of Nonpeptidic Inhibitors
zofuran ring is stacked parallel to Tyr225 and perpendic-The diffraction quality of crystals of C. albicans apo-
ular to Tyr354 in the proximity of Phe117 and Phe339.enzyme used in soaking experiments was moderate.
These residues are presumed to be important not onlyThe electron density, however, was clear enough to elu-
for the architecture of the binding site but also for inhibi-cidate the bound conformation of the inhibitors. A close-
tor binding. His227 is located in the proximity of theup view of the inhibitor binding site of the structure of C.
oxygen atom of the benzofuran ring. Since the inhibitoralbicans Nmt with compound 5 with an electron density
having a benzothiophene ring instead of a benzofuranmap is shown in Figure 2B. The binding conformation
ring showed about 1000-fold lower inhibitory activity,of nonpeptidic inhibitors was examined with reference
the hydrogen-bond interaction of the benzofuran ringto the results of site-directed mutagenesis analysis (see
with the imidazole ring of His227 and/or the geometrybelow). As expected, the main-chain conformation was
of the benzofuran ring might contribute to the inhibitornot changed by the soaking experiment (data not
binding [22].shown). Residues 108 to 113 of the Ab loop remain
disordered on inhibitor binding. Crystal structures of The secondary amine group of the substituent at posi-
Structures of Nmt with Two Distinct Inhibitors
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Figure 3. The Bound Conformation of Non-
peptidic Inhibitors
The side-chain atoms of surrounding resi-
dues analyzed by site-directed mutagenesis,
except for residues 108 to 113, are shown.
The main-chain atoms of Gly413 are also
shown. Compounds 2, 4, and 5 are shown in
yellow, green, and magenta, respectively.
tion 4 of the benzofuran ring makes a hydrogen bond The results of mutagenesis with SC-58272 agree with
those of structural analysis.with the C-terminal carboxylate. This hydrogen bond
formation accounts for our structure-activity relation- Enzyme inhibition constants were measured for two
nonpeptidic inhibitors, compounds 1 and 3 (Table 3).ships, which show that the secondary amine is essential
for the inhibitory activity [21]. The conformation of the Mutants of three residues (F117A, Y354A, and L451)
were significantly reduced in their inhibitor binding affin-aliphatic chain between the secondary amine and the
benzofuran ring is consistent with that elucidated by ity for both inhibitors. These residues are localized in
the substrate binding site. Y256A also showed reducedNMR spectroscopic analysis [31]. For the complex with
compound 4, Tyr119 is in the proximity of the pyridine affinity for both inhibitors, although Tyr256 is found
some distance away at the other end of the groove. Thisring that is not contained in compound 2. It is known
that the change of substituent from a tertiary butyl group residue may significantly affect protein folding, as it was
also observed that the enzymatic activity (Vmax/Km) wasto a 3-pyridylmethyl group improves the inhibitory activ-
ity [21]. The inhibition increase may be attributed to the reduced by mutation of Tyr256 (data not shown). Re-
placement of the side chain of Leu451 had little effectadditional hydrogen-bond interaction. The substituent
at position 2 of the benzofuran ring is surrounded by on inhibition constants, while its deletion had a large
effect. The crystal structures show that the side chain ofthe hydrophobic residues Phe115, Phe240, and Phe339.
For the complex with compound 4, the 2,3-fluorophenyl Leu451 has no interaction with the nonpeptidic inhibitor.
Different inhibition patterns for the two inhibitors maygroup is situated adjacent to Phe240, with the fluorine
atom positions on the phenyl ring not clearly defined. be correlated with their different substitution patterns.
Alanine mutation of Tyr119 did not affect the Ki value ofIn the complex with compound 5, the methylimidazole
ring makes a hydrogen-bond interaction with the side compound 1 but did affect that of compound 3. The
crystal structures show that this tyrosine residue makeschain of Asn392 and is positioned in close proximity to
Phe240. The substituent at position 2 is partially ex- a hydrogen bond with the pyridine ring not contained
in compound 1. Besides these residues, two more resi-posed to solvent, so that a bulky substituent seems to
be acceptable for enzyme inhibition. These observations dues, Tyr225 and His227, seem to be involved in the
inhibitor binding, as indicated by some changes of theare consistent with chemical modification studies [21,
22]. The disordered Ab loop (residues 108 to 113) might Ki values. The crystal structures show that Tyr225 stacks
with the benzofuran ring, being accompanied by struc-also be in the proximity of the substituent at position 2,
but no specific interaction was observed due to poor tural rearrangement (see below), and that His227 is situ-
ated close to the benzofuran ring. In summary, the muta-electron density.
genesis analysis identified several residues in the
substrate binding site near to the enzyme C terminusSite-Directed Mutagenesis
which seem to be critical for the binding of nonpeptidicA site-directed mutagenesis study was carried out in
inhibitors.order to better characterize the bound conformation
of the nonpeptidic inhibitors. A total of 29 mutants of
residues located at the substrate binding site were pro- Selectivity for Inhibitors
As shown in Table 1, a series of nonpeptidic inhibitorsduced. Only the mutant with Phe176 replaced by Ala
(F176A) was insoluble; the other 28 mutants were ex- exhibited high inhibitory activity against C. albicans Nmt
with low inhibitory activity against human Nmt. Suchpressed with almost the same level as the wild-type
and were purified by the same procedure (Table 3 and high selectivity between fungal and human Nmts is a
prerequisite for a good antifungal drug. IdentificationFigure 3).
The inhibitory activity for mutants was estimated by of specific residues associated with selectivity will aid
design of species-specific inhibitors of Nmts. The knownthe measurement of the Ki value for inhibitors. In this
way, the relative contribution of residues in the substrate crystal structures indicate that all Nmts have similar
polypeptide folding. There are, however, a few specificbinding site to inhibitor binding may be estimated. The
results for SC-58272 show that C-terminal carboxylate amino-acid differences in the inhibitor binding site be-
tween C. albicans Nmt and other Nmts. Phe339 andand the aromatic side chains of Phe115, Phe117, Tyr225,
Phe240, and Tyr256 significantly affect binding (Table Ile352 are replaced by serine and alanine, respectively,
in human Nmt. Leu350 is replaced by valine in A. fumiga-3). These residues are presumed to be important not
only for inhibitor binding but also for the architecture of tus Nmt. Leu451 is replaced by glutamine in human Nmt.
High selectivity of the inhibitors might be caused bythe binding site, as the long groove is defined by these
residues on binding of SC-58272. Asp112, His227, and these differences of surrounding residues. Several mu-
tants of C. albicans Nmt with a pseudo binding site fromAsp412 are also seen to function in inhibitor recognition.
Chemistry & Biology
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Table 3. The Inhibitory Activity for Mutants of C. albicans Nmt
Enzyme Inhibition (Ki: M)
SC-58272Compound 1 3
Wild type 0.25 0.60 0.03
Mutants
Y107A 2.0 (8.0) 1.7 (2.8) 0.07 (2.3)
V108A 0.15 (0.6) 0.69 (1.2) 0.07 (2.3)
D110A 3.2 (12.7) 0.39 (0.7) 0.03 (0.9)
I111A 0.35 (1.4) 2.6 (4.4) 0.46 (15.3)
D112A 10.6 (42.0) 0.14 (0.2) 0.03 (1.0)
T114A 0.08 (0.3) 0.45 (0.8) 0.04 (1.2)
F115A 50 (200) 0.28 (0.5) 0.02 (0.8)
F117A 50 (200) 89 (150) 10 (333)
Y119A 1.5 (5.9) 0.36 (0.6) 4.7 (158)
N175A 2.7 (10.7) 0.42 (0.7) 0.03 (1.0)
T211A 0.27 (1.1) 0.26 (0.4) 0.05 (1.7)
Y225A 50 (200) 2.2 (3.8) 0.46 (15.3)
H227A 7.4 (29.3) 1.9 (3.2) 3.2 (107)
P229A 0.30 (1.2) 0.54 (0.9) 0.05 (1.5)
W232A 0.84 (3.3) 0.45 (0.8) 0.10 (3.2)
F240A 50 (200) 0.24 (0.4) 0.09 (3.1)
S241A 0.77 (3.1) 1.1 (1.8) 0.24 (8.0)
Y256A 50 (200) 6.9 (11.5) 10 (333)
F339A 1.8 (7.3) 1.0 (1.7) 0.22 (7.3)
F339S 0.09 (3.1)
L350V 0.2 (0.7) 0.04 (1.3)
I352A 1.8 (7.3) 0.45 (0.8) 0.07 (2.2)
Y354A 2.2 (8.7) 89 (150) 10 (333)
D412A 21.8 (86.7) 0.05 (0.1) 0.03 (1.1)
G413A 0.18 (0.7) 0.86 (1.5) 0.11 (3.5)
L451A 0.25 (1.0) 0.54 (0.9) 0.15 (5.0)
L451Q 0.65 (2.6) 0.54 (18.0)
L451 50 (200) 89 (150) 10 (333)
The ratio of Ki values of mutant to that of wild-type are shown in parentheses.
different species were prepared in order to understand the absence of myristoyl-CoA, although kinetics studies
indicate that the nonpeptidic inhibitor is competitive forthe difference of inhibitory activity for Nmts (F339S,
L350V, I352A, and L451Q). No increase of the Ki value peptide substrate binding [21]. It remains uncertain
whether the nonpeptidic inhibitor is bound to the en-greater than 100-fold was observed for any single-resi-
due mutation (Table 3). We conclude that the inhibitory zyme prior to the binding of myristoyl-CoA under physio-
logical conditions. Myristoyl-CoA was not included inspecificity of the inhibitors is caused by more than one
amino-acid difference. The selectivity is most likely a the soaking experiments purely because of solubility
problems. The residues in which the inhibitory activityconcerted effect of the residues that lie adjacent to the
inhibitors. Therefore, structural information of human is diminished or abolished by site-directed mutagenesis
are quite consistent with those which make interactionsNmt is necessary to rationalize the selectivity of these
inhibitors. with the nonpeptidic inhibitors in the crystal structures.
These considerations suggest that the bound conforma-
tion of the nonpeptidic inhibitor in the crystal is closelyRecognition of Inhibitors
similar to that in solution. Even though nonpeptidic in-The ternary complex of C. albicans Nmt with myristoyl-
hibitors have no interaction with the Ab loop, theyCoA and SC-58272 reveals the locations and interac-
showed quite strong inhibitory activity. We suggest thattions of myristoyl-CoA and the peptide substrate in-
additional substituents designed to interact with the Abvolved in the acyl transfer reaction. It was previously
loop might further improve enzyme inhibition.proposed that the ordered Bi-Bi reaction mechanism is
The total solvent-accessible surface area of the sub-attributed to the ordering and disordering of the Ab loop
strate binding site of the apo-enzyme is larger than thatby myristoyl-CoA binding and CoA release, respectively
of the complex with SC-58272, a substrate analog,[27, 28]. Our work supports this proposal. The apo-
which means that the substrate binding site of the apo-enzyme is known to have very low affinity for substrate
enzyme has greater exposure to solvent in comparisonprotein or peptides, implying that the binding of myris-
with the complex with peptide substrate. Comparisontoyl-CoA to the enzyme is required for the formation of
of the two structures reveals that the region of residuesa functional peptide binding site [32]. In the complex
114 to 120 (strand b) is shifted to cover the peptidicwith nonpeptidic inhibitors, the Ab loop is disordered
inhibitor (Figure 4A). Although the resolution level amongand makes no prominent interaction with the nonpep-
structures is different, conformational changes are cleartidic inhibitor. The crystal structures also indicate that
the nonpeptidic inhibitors can bind to the enzyme in from this structural analysis. These conformational
Structures of Nmt with Two Distinct Inhibitors
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Figure 4. The Inhibitor Binding Site
(A) The secondary-structure differences. The
structures of Nmt complexed with SC-58272
and with compound 5 are drawn in green and
cyan, respectively. The inhibitors and 
strand b [27] are highlighted in orange and
magenta for each structure, respectively. The
disordered Ab loop in the complex with com-
pound 5 is transparent.
(B) The side-chain conformation differences.
Hydrogen bonds are depicted with dashed
yellow lines. Only side-chain atoms are drawn
except those of the C-terminal residue
(Leu451), in which only the main-chain atoms
are drawn.
changes result in enlargement of the binding site and the substrate binding site surrounded by hydrophobic
residues, making interactions different in detail frominteraction with the secondary amine of the nonpeptidic
inhibitor. The side-chain conformations in the vicinity of those made by the peptidic inhibitor. Site-directed mu-
tagenesis studies have provided valuable informationthe inhibitor were compared between the complexes of
the peptidic and nonpeptidic inhibitors (Figure 4B). A for the interpretation of the structure-activity relation-
ships for a variety of inhibitors. The binding conforma-rearrangement of the side chain of Tyr225, which has
no direct interaction with SC-58272, accompanies non- tion of the inhibitor appears to be dominated by the
interactions of its protonated amino group with thepeptidic inhibitor binding. Structural adjustments of aro-
matic residues Phe117, Tyr119, and Tyr354 were ob- C-terminal carboxylate of the enzyme. However, it is
currently impossible to state with certainty which resi-served. These conformation changes indicate that the
peptide substrate is trapped by the closure of the en- dues contribute most to the species selectivity. Fur-
ther structural analysis of other Nmts and chemicalzyme in the catalytic reaction and that the nonpeptidic
inhibitor binds deep in the binding site and thus prevents modification of inhibitors would help to solve this
question.peptide substrate binding. Further inhibitor design
should be performed with the prospect of protein flexi-
bility. Experimental Procedures
Expression and PurificationSignificance
Nmt was produced in E. coli and purified as described previously
[33] with an additional chromatography step. The gene coding forMyristoyl-CoA:protein N-myristoyltransferase (Nmt)
C. albicans Nmt was assembled into the T7 promoter expressionattaches myristate to the proteins involved in a variety
plasmid (pT7-7, Stratagene). The E. coli strain BL21(DE3) (Stra-
of signal transduction cascades and other critical cel- tagene) transformed by the Nmt expression plasmid was grown in
lular functions. The enzyme is essential for viability of modified Terribic Broth medium [1.2% tryptone, 1.2% yeast extract,
0.4% (v/v) glycerol, 40 mM phosphate buffer (pH 7.0)]. Protein ex-Candida albicans, which is a major cause of systemic
pression was induced by IPTG (isopropyl--D-thiogalactopyrano-fungal infections in immunocompromised patients.
side), and then the cells were harvested after incubation for a fewThus, Nmt is a potential target for the development of
hours at 37C. All subsequent purification steps were carried out atan antifungal drug. The crystal structures of C. albi-
4C. Wet cells were suspended into buffer A (30 mM MES [pH 6.5],
cans Nmt with peptidic and nonpeptidic inhibitors pre- 50 mM KCl, 2 mM EDTA, 2 mM PMSF [phenylmethylsulfonylfluoride])
sented here contribute to understanding changes of and were sonicated followed by ultracentrifugation. The recombi-
nant enzyme was purified from the lysate supernatants by cation-the enzyme structure to enable substrate recognition
exchange chromatography on S-sepharose (Pharmacia) followedand suggest ways in which the inhibitors might be
by chromatography on P11 phospho-cellulose column (Whatman)improved. The enzyme has an opened conformation
as described previously [12]. The purified enzyme was dialyzedfor substrate binding, and the nonpeptidic inhibitor
against 30 mM MES (pH 6.5) for crystallization trials. The purity index
prevents the adoption of a closed conformation. A of the final product was judged by SDS-PAGE. Alanine substitution
comprehensive analysis of the substrate binding site mutants in the Nmt gene were programmed by site-directed muta-
genesis using synthetic oligonucleotides. The presence of the de-demonstrates that the nonpeptidic inhibitor binds to
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sired mutation was confirmed by DNA sequencing of the insert. The ous heavy atoms for set periods of time. For the first derivative,
ethylmercury chloride, the positions of two sites were determinedmutant enzymes were purified using the same protocol as described
above. by direct inspection of difference Patterson maps using RSPS [36].
Sites for the second derivative, chloro(2,2:6’,2”-terpyridine) platinum
(II), were determined by the use of difference Fourier maps, whichInhibitor Synthesis
were phased from the mercury derivative. Heavy atom parametersSC-58272 was prepared by the method reported by Devadas et al.
were refined with MLPHARE [39]. An initial MIR map at 15.3 A˚ resolu-[20]. The analytical data were consistent with the structure. FAB-
tion was calculated from the Hg and Pt derivative data, with meanMS (m-nitrobenzyl alcohol), m/z 597 (MH); 1H-NMR, identical with
figure-of-merit of 0.52. This electron density was modified by solventthe reported data. The purity of SC-58272 was confirmed by HPLC
flipping using SOLOMON [40] by solvent flattening with noncrystallo-analysis using a TOSOH CCPS with Photal MCPD-3600 photodiode
graphic symmetry averaging using DM [41] and phase extension toarray detector (OHTSUKA ELECTRONICS) with an analytical column
2.7 A˚. The resulting electron density map was of sufficient quality(MCI GEL ODS-1MU/4.6  150 mm). A gradient system of acetoni-
to interpret. An atomic model of the polypeptide chains was builttrile (pump A) and 0.015 M potassium phosphate buffer (pH 3.5)
using O [42] and Moloc [43]. Simulated annealing refinement fol-(pump B) was used. The gradient program was made up of linear
lowed by positional refinement and individual B factor refinementsegments (15/85 A/B to 98/2 A/B over 40 min), and the flow rate
was performed at 2.3 A˚ resolution using the program CNX (Accelryswas 1.2 ml/min. SC-58272 was detected as a single peak at 10.2 min.
Inc.) with application of a bulk-solvent correction and with no ampli-Compounds 1–5 were prepared as previously described [21, 22].
tude cut-off. The free R factor was monitored as an indicator of
model improvement throughout the refinement. The final model wasCrystallization
examined using the program PROCHECK [44] and SFCHECK [45].In order to prepare a ternary Nmt:myristoyl-CoA:SC-58272 complex,
Solvent molecules were placed according to criteria of distance andthe enzyme was concentrated to 60 mg/ml and was incubated with
a temperature factor.5-fold excess molar of myristoyl-CoA and the inhibitor for a few
The structure of the complex with nonpeptidic inhibitors washours at 4C. Crystals were grown at 4C in hanging drops over
solved by molecular replacement using the structure with removed10%–12% (w/v) polyethylene glycol 3350, 0.2 M ammonium acetate,
myristoyl-CoA and SC-58272 as a search model. A crossrotationand 50 mM HEPES (pH 7.5). Crystals generally appeared within 2–3
function and a translation function using the monomer model (resi-weeks with a maximum size of 0.6  0.6  0.2 mm. The result of
dues 82 to 451) were calculated by AMORE [46]. Four clear solutionsthe SDS-PAGE of the dissolved crystals showed that the molecular
were identified using data between 8.0–4.0 A˚. The models wereweight of the protein was about 45 kDa. The activity of the crystal-
refined using positional refinement and grouped B factor refinementlized enzyme, however, remains the same as that of the starting
at 3.2 or 3.5 A˚ resolution by the programs CNX (Accelrys Inc.). Thematerial. The molecular weight of the crystallized enzyme was deter-
parameter and topology files for the nonpeptidic inhibitors weremined as 46 kDa by mass spectroscopy. The cleavage site of the
obtained using Moloc [43]. Noncrystallographic symmetry restraintsenzyme, as determined by N-terminal amino-acid sequencing, was
were applied to residues 82 to 451. It was found that two moleculesbefore residue Gln60. The crystals belong to the orthorhombic crys-
had significantly higher temperature factors than the others. Aftertal system with space group P212121 and unit-cell constants a 
refinement of the polypeptide chains, examination of 
A-weighted58.7 A˚, b  95.3 A˚, and c  176.5 A˚. There are two molecules in
simulated-annealing omit maps [47] clearly indicated that thethe asymmetric unit, with VM [34] of 2.7 A˚3 /Da. In order to obtain
patches of strong residual electron density at the substrate bindingcomplexes with the nonpeptidic inhibitors, soaking experiments
site were interpretable as the inhibitor. The model of the inhibitor waswere tried using these crystals. No conditions were found in which
built into the electron density using Moloc [43]. The final refinementit was possible to displace SC-58272. Further, no cocrystals of the
statistics are listed in Table 2. The volume of the binding pocket forenzyme with the nonpeptidic inhibitors were obtained. In order to
each structure was calculated using the program XSAE (C. Broger,prepare complexes with the nonpeptidic inhibitors, crystals of the
personal communication).apo-enzyme were grown using a reservoir solution that contained
The figures were generated using the programs MOLSCRIPT [48],15%–18% (w/v) polyethylene glycol 3350, 0.2 M lithium sulfate, and
RASTER3D [49], CONSCRIPT [50], and LIGPLOT [51].50 mM HEPES (pH 7.5). Inhibitors were soaked into the preformed
crystals over a period of 3 hr using the reservoir solution containing
Acknowledgments1% (v/v) DMSO. These crystals were of space group P212121 with
unit-cell dimensions a  93.3 A˚, b  96.9 A˚, and c  269.3 A˚. This
We thank Drs. Suzuki and Igarashi and Prof. Sakabe at the Photonunit cell gives a VM of 3.4 A˚3 /Da for four molecules per asymmetric
Factory for assistance with the beam line station (BL6B). S.S. andunit.
T.A.F. are members of Structure Biology Sakabe Project in Founda-
tion for Advancement of International Science. Thanks are also dueData Collection and Processing
to Ms. F. Ford for proofreading the manuscript.All diffraction data were collected at room temperature using crys-
tals mounted in glass capillaries. The diffraction data of crystals of
Received: June 24, 2002the complex with SC-58272 were collected on an imaging plate
Revised: Spetember 9, 2002detector (MarResearch) mounted on a copper rotating-anode X-ray
Accepted: September 11, 2002generator (ENRAF NONIUS FR591) equipped with double focusing
optical mirrors (SUPPER). The data collection for heavy-atom deriv-
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Accession Numbers
The coordinates of the complexes with SC-58272 and compound
5 have been deposited in the Protein Data Bank under ID codes
1IYK and 1IYL, respectively.
